ArticleEndocrine2025
Long-term follow-up of growth and puberty in 3-M syndrome: effects of growth hormone therapy and response variability.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose3-M syndrome is a rare autosomal recessive growth disorder characterised by severe prenatal and postnatal growth retardation, resulting from mutations in the CUL7, OBSL1, or CCDC8 genes. This study aimed to assess the effects of recombinant human growth hormone (rhGH) therapy in individuals with 3-M syndrome.
methodsA retrospective analysis was conducted on 24 patients (19 males and 5 females) from 16 unrelated families, all with clinically and genetically confirmed diagnoses of 3-M syndrome. Growth patterns and pubertal development were evaluated.
resultsThe median age of the patients was 6.8 years (0.5–21.2). Thirteen families were consanguineous. Median birth weight SDS was −3.8 (−6.3 to −1.4), with all patients born small for gestational age (SGA), except for one patient. All individuals presented with marked growth retardation, with a median height SDS of −4.1 (−7.9 to −2.7). Dysmorphic features characteristic of 3-M syndrome and delayed bone age were observed in all patients. Genetic testing identified pathogenic or likely pathogenic variants in CUL7 in 4 families (25%) and in OBSL1 in the remaining 75%. The rhGH therapy was initiated in 13 patients, with a median starting age of 7.5 years (2.4–13.1) and treatment duration ranging from 1 to 7 years. The overall median change in height SDS was +0.3 (–0.8 to +2.3), reflecting variability in response among patients receiving treatment. A favorable response was observed in 7 out of 13 patients (54%). Pubertal arrest was noted in seven male patients, while two female siblings and one male patient experienced rapidly progressive puberty.
conclusion3-M syndrome should be included in the differential diagnosis of individuals presenting with severe prenatal and postnatal growth retardation. The rhGH therapy may offer benefit in some cases, although response is variable. Pubertal arrest can occur in males with 3-M syndrome.
Indexed as
Identifiers
40974508What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.